Repurposing Metformin: Potential as a Prevention, Treatment and Adjunct Therapy in Pancreatic Cancer
DOI:
https://doi.org/10.12775/QS.2024.36.56451Keywords
metformin, glycemic control, pancreatic cancer, oncologyAbstract
Metformin, a widely prescribed treatment for type II diabetes, offers promising benefits beyond glycemic control, including improved lipid profiles and cardiovascular outcomes. It inhibits gluconeogenesis in the liver by activating AMPK, thereby reducing glucose production and enhancing glucose uptake in muscle. Recent studies highlight its potential anticancer effects, particularly through the suppression of the mTOR pathway via LKB1-dependent AMPK activation, which inhibits cell proliferation. This review explores metformin’s role as an adjunct therapy in pancreatic cancer, summarizing evidence on its molecular mechanisms and potential efficacy. The findings suggest metformin’s broader therapeutic applications, especially in oncology, warrant further investigation.
The aim: The aim of this study is to analyze the role of metformin as an adjunct therapy in the treatment of pancreatic cancer, with particular focus on its molecular mechanisms, such as AMPK activation and mTOR pathway inhibition. The study aims to summarize the current scientific evidence regarding its potential effectiveness.
References
Ben Sahra, I.; Le Marchand-Brustel, Y.; Tanti, J.-F.; Bost, F. Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? Molecular Cancer Therapeutics 2010, 9, 1092–1099, doi:10.1158/1535-7163.MCT-09-1186.
Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34). The Lancet 1998, 352, 854–865, doi:10.1016/S0140-6736(98)07037-8.
Sharma, M.; Nazareth, I.; Petersen, I. Trends in Incidence, Prevalence and Prescribing in Type 2 Diabetes Mellitus between 2000 and 2013 in Primary Care: A Retrospective Cohort Study. BMJ Open 2016, 6, e010210, doi:10.1136/bmjopen-2015-010210.
Wiernsperger, N.F.; Bailey, C.J. The Antihyperglycaemic Effect of Metformin: Therapeutic and Cellular Mechanisms. Drugs 1999, 58, 31–39, doi:10.2165/00003495-199958001-00009.
Hundal, R.S.; Krssak, M.; Dufour, S.; Laurent, D.; Lebon, V.; Chandramouli, V.; Inzucchi, S.E.; Schumann, W.C.; Petersen, K.F.; Landau, B.R.; et al. Mechanism by Which Metformin Reduces Glucose Production in Type 2 Diabetes. Diabetes 2000, 49, 2063–2069, doi:10.2337/diabetes.49.12.2063.
Galuska, D.; Nolte, L.A.; Zierath, J.R.; Wallberg-Henriksson, H. Effect of Metformin on Insulin-Stimulated Glucose Transport in Isolated Skeletal Muscle Obtained from Patients with NIDDM. Diabetologia 1994, 37, 826–832, doi:10.1007/BF00404340.
Wu, M.-S.; Johnston, P.; Sheu, W.-H.; Hollenbeck, C.; Jeng, C.-Y.; Goldfine, I.; Chen, Y.-D.; Reaven, G. Effect of Metformin on Carbohydrate and Lipoprotein Metabolism in NIDDM Patients. Diabetes Care 1990, 13, 1–8, doi:10.2337/diacare.13.1.1.
Suh, S. Metformin-Associated Lactic Acidosis. Endocrinol Metab 2015, 30, 45, doi:10.3803/EnM.2015.30.1.45.
Foretz, M.; Guigas, B.; Viollet, B. Understanding the Glucoregulatory Mechanisms of Metformin in Type 2 Diabetes Mellitus. Nat Rev Endocrinol 2019, 15, 569–589, doi:10.1038/s41574-019-0242-2.
An, H.; He, L. Current Understanding of Metformin Effect on the Control of Hyperglycemia in Diabetes. Journal of Endocrinology 2016, 228, R97–R106, doi:10.1530/JOE-15-0447.
Pernicova, I.; Korbonits, M. Metformin—Mode of Action and Clinical Implications for Diabetes and Cancer. Nat Rev Endocrinol 2014, 10, 143–156, doi:10.1038/nrendo.2013.256.
Hardie, D.G.; Carling, D. The AMP‐Activated Protein Kinase: Fuel Gauge of the Mammalian Cell? European Journal of Biochemistry 1997, 246, 259–273, doi:10.1111/j.1432-1033.1997.00259.x.
Giovannucci, E.; Harlan, D.M.; Archer, M.C.; Bergenstal, R.M.; Gapstur, S.M.; Habel, L.A.; Pollak, M.; Regensteiner, J.G.; Yee, D. Diabetes and Cancer. Diabetes Care 2010, 33, 1674–1685, doi:10.2337/dc10-0666.
Gallagher, E.J.; LeRoith, D. Diabetes, Antihyperglycemic Medications and Cancer Risk: Smoke or Fire? Current Opinion in Endocrinology, Diabetes & Obesity 2013, 20, 485–494, doi:10.1097/01.med.0000433065.16918.83.
Chen, G.; Xu, S.; Renko, K.; Derwahl, M. Metformin Inhibits Growth of Thyroid Carcinoma Cells, Suppresses Self-Renewal of Derived Cancer Stem Cells, and Potentiates the Effect of Chemotherapeutic Agents. The Journal of Clinical Endocrinology & Metabolism 2012, 97, E510–E520, doi:10.1210/jc.2011-1754.
Gong, J.; Kelekar, G.; Shen, J.; Shen, J.; Kaur, S.; Mita, M. The Expanding Role of Metformin in Cancer: An Update on Antitumor Mechanisms and Clinical Development. Targ Oncol 2016, 11, 447–467, doi:10.1007/s11523-016-0423-z.
Tomimoto, A.; Endo, H.; Sugiyama, M.; Fujisawa, T.; Hosono, K.; Takahashi, H.; Nakajima, N.; Nagashima, Y.; Wada, K.; Nakagama, H.; et al. Metformin Suppresses Intestinal Polyp Growth in ApcMin/+ Mice. Cancer Science 2008, 99, 2136–2141, doi:10.1111/j.1349-7006.2008.00933.x.
Ece, H.; Cigdem, E.; Yuksel, K.; Ahmet, D.; Hakan, E.; Oktay, T.M. Use of Oral Antidiabetic Drugs (Metformin and Pioglitazone) in Diabetic Patients with Breast Cancer: How Does It Effect on Serum Hif-1 Alpha and 8Ohdg Levels? Asian Pacific Journal of Cancer Prevention 2012, 13, 5143–5148, doi:10.7314/APJCP.2012.13.10.5143.
Wang, Y.; Zhang, M.-X.; Duan, X.; Zhou, S.; Ermek, T.; Wang, Y.; Cai, H.; Wang, J. [Effects of antidiabetic drug metformin on human breast carcinoma cells with different estrogen receptor expressing in vitro]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2011, 27, 253–256.
Shaw, R.J.; Lamia, K.A.; Vasquez, D.; Koo, S.-H.; Bardeesy, N.; DePinho, R.A.; Montminy, M.; Cantley, L.C. The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin. Science 2005, 310, 1642–1646, doi:10.1126/science.1120781.
Hardie, D.G. AMPK and Raptor: Matching Cell Growth to Energy Supply. Molecular Cell 2008, 30, 263–265, doi:10.1016/j.molcel.2008.04.012.
Borun, P.; De Rosa, M.; Nedoszytko, B.; Walkowiak, J.; Plawski, A. Specific Alu Elements Involved in a Significant Percentage of Copy Number Variations of the STK11 Gene in Patients with Peutz–Jeghers Syndrome. Familial Cancer 2015, 14, 455–461, doi:10.1007/s10689-015-9800-5.
Rahib, L.; Smith, B.D.; Aizenberg, R.; Rosenzweig, A.B.; Fleshman, J.M.; Matrisian, L.M. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Research 2014, 74, 2913–2921, doi:10.1158/0008-5472.CAN-14-0155.
Kolbeinsson, H.M.; Chandana, S.; Wright, G.P.; Chung, M. Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. Journal of Investigative Surgery 2023, 36, 2129884, doi:10.1080/08941939.2022.2129884.
Eibl, G.; Cruz-Monserrate, Z.; Korc, M.; Petrov, M.S.; Goodarzi, M.O.; Fisher, W.E.; Habtezion, A.; Lugea, A.; Pandol, S.J.; Hart, P.A.; et al. Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer. Journal of the Academy of Nutrition and Dietetics 2018, 118, 555–567, doi:10.1016/j.jand.2017.07.005.
Bartosch-Härlid, A.; Andersson, R. Diabetes Mellitus in Pancreatic Cancer and the Need for Diagnosis of Asymptomatic Disease. Pancreatology 2010, 10, 423–428, doi:10.1159/000264676.
Dhillon, J.; Betancourt, M. Pancreatic Ductal Adenocarcinoma. In Monographs in Clinical Cytology; Centeno, B.A., Dhillon, J., Eds.; S. Karger AG, 2020; Vol. 26, pp. 74–91 ISBN 978-3-318-06603-6.
Li, D.; Yeung, S.J.; Hassan, M.M.; Konopleva, M.; Abbruzzese, J.L. Antidiabetic Therapies Affect Risk of Pancreatic Cancer. Gastroenterology 2009, 137, 482–488, doi:10.1053/j.gastro.2009.04.013.
Zhang, P.; Li, H.; Tan, X.; Chen, L.; Wang, S. Association of Metformin Use with Cancer Incidence and Mortality: A Meta-Analysis. Cancer Epidemiology 2013, 37, 207–218, doi:10.1016/j.canep.2012.12.009.
Hu, J.; Fan, H.-D.; Gong, J.-P.; Mao, Q.-S. The Relationship between the Use of Metformin and the Risk of Pancreatic Cancer in Patients with Diabetes: A Systematic Review and Meta-Analysis. BMC Gastroenterol 2023, 23, 50, doi:10.1186/s12876-023-02671-0.
Skuli, S.J.; Alomari, S.; Gaitsch, H.; Bakayoko, A.; Skuli, N.; Tyler, B.M. Metformin and Cancer, an Ambiguanidous Relationship. Pharmaceuticals 2022, 15, 626, doi:10.3390/ph15050626.
Lee, S.H.; Yoon, S.H.; Lee, H.S.; Chung, M.J.; Park, J.Y.; Park, S.W.; Song, S.Y.; Chung, J.B.; Bang, S. Can Metformin Change the Prognosis of Pancreatic Cancer? Retrospective Study for Pancreatic Cancer Patients with Pre-Existing Diabetes Mellitus Type 2. Digestive and Liver Disease 2016, 48, 435–440, doi:10.1016/j.dld.2015.12.006.
Sadeghi, N.; Abbruzzese, J.L.; Yeung, S.-C.J.; Hassan, M.; Li, D. Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer. Clinical Cancer Research 2012, 18, 2905–2912, doi:10.1158/1078-0432.CCR-11-2994.
Li, X.; Li, T.; Liu, Z.; Gou, S.; Wang, C. The Effect of Metformin on Survival of Patients with Pancreatic Cancer: A Meta-Analysis. Sci Rep 2017, 7, 5825, doi:10.1038/s41598-017-06207-x.
Wan, G.; Sun, X.; Li, F.; Wang, X.; Li, C.; Li, H.; Yu, X.; Cao, F. Survival Benefit of Metformin Adjuvant Treatment For Pancreatic Cancer Patients: A Systematic Review and Meta-Analysis. Cell Physiol Biochem 2018, 49, 837–847, doi:10.1159/000493214.
Yoo, D.; Kim, N.; Hwang, D.W.; Song, K.B.; Lee, J.H.; Lee, W.; Kwon, J.; Park, Y.; Hong, S.; Lee, J.W.; et al. Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma. JCM 2020, 9, 1953, doi:10.3390/jcm9061953.
Hwang, A.L.; Haynes, K.; Hwang, W.-T.; Yang, Y.-X. Metformin and Survival in Pancreatic Cancer: A Retrospective Cohort Study. Pancreas 2013, 42, 1054–1059, doi:10.1097/MPA.0b013e3182965a3c.
Chaiteerakij, R.; Petersen, G.M.; Bamlet, W.R.; Chaffee, K.G.; Zhen, D.B.; Burch, P.A.; Leof, E.R.; Roberts, L.R.; Oberg, A.L. Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. JCO 2016, 34, 1898–1904, doi:10.1200/JCO.2015.63.3511.
DeCensi, A.; Puntoni, M.; Goodwin, P.; Cazzaniga, M.; Gennari, A.; Bonanni, B.; Gandini, S. Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis. Cancer Prevention Research 2010, 3, 1451–1461, doi:10.1158/1940-6207.CAPR-10-0157.
Currie, C.J.; Poole, C.D.; Gale, E.A.M. The Influence of Glucose-Lowering Therapies on Cancer Risk in Type 2 Diabetes. Diabetologia 2009, 52, 1766–1777, doi:10.1007/s00125-009-1440-6.
Zhou, D.-C.; Gong, H.; Tan, C.-Q.; Luo, J.-Q. Prognostic Significance of Anti-Diabetic Medications in Pancreatic Cancer: A Meta-Analysis. Oncotarget 2017, 8, 62349–62357, doi:10.18632/oncotarget.17728.
Kordes, S.; Pollak, M.N.; Zwinderman, A.H.; Mathôt, R.A.; Weterman, M.J.; Beeker, A.; Punt, C.J.; Richel, D.J.; Wilmink, J.W. Metformin in Patients with Advanced Pancreatic Cancer: A Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial. The Lancet Oncology 2015, 16, 839–847, doi:10.1016/S1470-2045(15)00027-3.
Reni, M.; Dugnani, E.; Cereda, S.; Belli, C.; Balzano, G.; Nicoletti, R.; Liberati, D.; Pasquale, V.; Scavini, M.; Maggiora, P.; et al. (Ir)Relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Clinical Cancer Research 2016, 22, 1076–1085, doi:10.1158/1078-0432.CCR-15-1722.
Pretta, A.; Ziranu, P.; Giampieri, R.; Donisi, C.; Cimbro, E.; Spanu, D.; Lai, E.; Pecci, F.; Balconi, F.; Lupi, A.; et al. Influence of Antidiabetic Drugs on Glucose Metabolism and Immune Response in Patients with Metastatic Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine plus Nab-Paclitaxel as First-Line Treatment. Digestive and Liver Disease 2023, 55, 655–660, doi:10.1016/j.dld.2022.11.012.
Braghiroli, M.I.; De Celis Ferrari, A.C.R.; Pfiffer, T.E.; Kichfy Alex, A.; Nebuloni, D.; Carneiro, A.S.; Caparelli, F.; Senna, L.; Lobo, J.; Hoff, P.M.; et al. Phase II Trial of Metformin and Paclitaxel for Patients with Gemcitabine-Refractory Advanced Adenocarcinoma of the Pancreas. ecancer 2015, 9, doi:10.3332/ecancer.2015.563.
Ajumeera, R.; Thipparapu, G.; Padya, B.S.; Tirumala, L.; Challa, S. Anti-Cancer Activity of Pyridoxal Phosphate and Metformin Combination in Human Pancreatic Cancer Cells. Nutr Health 2022, 02601060221137624, doi:10.1177/02601060221137624
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Emilia Kamizela, Anna Rudzińska, Kacper Ponikowski, Kacper Wrzosek, Paulina Gumółka, Jakub Oberda, Alicja Paluch, Sylwia Haba, Karol Jakubik, Eliza Kolasa, Katarzyna Szklener
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 74
Number of citations: 0
